Log In
BCIQ
Print this Print this
 

ISV-101

  Manage Alerts
Collapse Summary General Information
Company Sun Pharmaceutical Industries Ltd.
DescriptionLow-dose bromfenac, an NSAID, delivered via InSite's DuraSite technology
Molecular Target
Mechanism of ActionNSAID
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationDry eye
Indication DetailsTreat dry eye disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$71.5M

$48.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today